Sareum Holdings plc (AIM: SAR)

Market Cap	30.22M
Revenue (ttm)	n/a
Net Income (ttm)	-4.26M
Shares Out	107.95M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	98,687
Open	n/a
Previous Close	28.50
Day's Range	26.25 - 29.00
52-Week Range	10.00 - 85.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2024

About Sareum Holdings

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company’s lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases. Its also developing SDC-1802, a TYK2/JAK1 inhibitor, which is in preclinical stage for cancer and cancer-immunothera...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 5
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: SAR